Massachusetts Secures Major Federal Awards to Advance Breakthrough Health Technologies

Massachusetts Secures Major Federal Awards to Advance Breakthrough Health Technologies 

MIT selected to develop breakthrough tear-based health monitoring technology; two Massachusetts companies to pioneer new treatments targeting the lymphatic system 

 

BOSTON — Governor Maura Healey today celebrated three competitive federal awards to Massachusetts organizations through the Advanced Research Projects Agency for Health (ARPA-H), a federal agency that invests in high-risk, high-reward research designed to accelerate breakthroughs in health and medicine. The awards will support groundbreaking efforts at the Massachusetts Institute of Technology (MIT) and two Boston-based companies, Ropirio Therapeutics and Seaport Therapeutics, working at the frontiers of life science innovation. 

 

The MIT award will advance the development of tiny sensors capable of continuously analyzing biomarkers in human tears, enabling real-time monitoring of a patient’s health and allowing treatments to be adjusted automatically based on live data. Ropirio Therapeutics and Seaport Therapeutics secured federal support to develop new therapies that directly repair abnormal lymphatic structure and function, an area of medicine where most current treatments manage symptoms rather than address the underlying problem. 

 

“These awards show why Massachusetts continues to lead the world in life sciences and biomedical innovation,” said Governor Maura Healey. “From developing entirely new ways to monitor disease to pioneering therapies that target the root causes of chronic disease, our researchers and companies are taking on some of the toughest challenges in medicine. We’re proud to see federal investment flowing to Massachusetts institutions that are improving lives and strengthening our innovation economy, and we’re grateful to our incredible Congressional delegation for their ongoing commitment to this initiative.” 

 

“Massachusetts has built a research ecosystem that makes bold ideas possible,” said Lieutenant Governor Kim Driscoll. “When federal agencies look for partners to tackle high-risk, high-impact challenges, they look here. These awards will accelerate breakthrough technologies while creating opportunities for growth and job creation across the state.” 

 

“These ARPA-H awards highlight the depth of talent across our universities and emerging companies,” said Secretary of Economic Development Eric Paley. “Massachusetts is uniquely positioned at the intersection of science, engineering, and AI. Investments like these help translate cutting-edge research into real-world therapies and reinforce our leadership in next-generation health technologies.” 

 

“Massachusetts continues to set the national standard as the leading hub for life sciences innovation,” said Massachusetts Life Sciences Center, President and CEO, Kirk Taylor, MD. “These ARPA-H awards underscore the extraordinary strength of our ecosystem and our unmatched ability to translate bold ideas into transformative medical breakthroughs that improve and save the lives of patients around the world.” 

 

ARPA-H announced today it had selected MIT for funding through its Ocular Laboratory for Analysis of Biomarkers (OCULAB) program, which seeks to create a continuous health monitoring system that resides in a patient’s tear duct. While most medical diagnostics today rely on blood tests taken at a single point in time, OCULAB aims to develop advanced sensors that continuously analyze tear chemistry. Tears contain many of the same biomarkers found in blood and are constantly present, offering the potential for minimally invasive, real-time monitoring. 

 

Ropirio Therapeutics and Seaport Therapeutics, received awards through ARPA-H’s Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE) program, which aims to transform treatment of diseases linked to lymphatic dysfunction such as heart disease and autoimmune disorders. Ropirio Therapeutics will create a first-of-its-kind drug that stops lymphatic vessels from leaking and collapsing, a root cause of fluid buildup and chronic swelling, while Seaport Therapeutics will help create an oral therapy that targets lymphatic inflammation, a key driver of central obesity.  

 

The OCULAB program will provide selected projects with a combined total of up to $68 million over four years and the GLIDE program up to $158 million total to selected companies over five years. 

Since ARPA-H’s launch, Massachusetts organizations and companies have secured more than $330 million in funding to advance breakthrough health technologies. In 2023, Massachusetts was selected as the location of ARPA-H’s Investor Catalyst Hub, a national center designed to help accelerate the commercialization and scaling of transformative medical innovations.